These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 33092601)

  • 1. Correction to: Trastuzumab-induced upregulation of a protein set in extracellular vesicles emitted by ErbB2-positive breast cancer cells correlates with their trastuzumab sensitivity.
    Drucker A; Yoo BH; Khan IA; Choi D; Montermini L; Liu X; Jovanovic S; Younis T; Rosen KV
    Breast Cancer Res; 2020 Oct; 22(1):110. PubMed ID: 33092601
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ErbB2-driven downregulation of the transcription factor Irf6 in breast epithelial cells is required for their 3D growth.
    Khan IA; Yoo BH; McPhee M; Masson O; Surette A; Dakin-Hache K; Younis T; Bethune G; Rosen KV
    Breast Cancer Res; 2018 Dec; 20(1):151. PubMed ID: 30545388
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Correction to: Trastuzumab, pertuzumab, and eribulin mesylate versus trastuzumab, pertuzumab, and a taxane as a first-line or second-line treatment for HER2-positive, locally advanced or metastatic breast cancer: study protocol for a randomized controlled, non-inferiority, phase III trial in Japan (JBCRG-M06/EMERALD).
    Yamashita T; Masuda N; Saji S; Araki K; Ito Y; Takano T; Takahashi M; Tsurutani J; Koizumi K; Kitada M; Kojima Y; Sagara Y; Tada H; Iwasa T; Kadoya T; Iwatani T; Hasegawa H; Morita S; Ohno S
    Trials; 2020 Jun; 21(1):503. PubMed ID: 32513251
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rac1 contributes to trastuzumab resistance of breast cancer cells: Rac1 as a potential therapeutic target for the treatment of trastuzumab-resistant breast cancer.
    Dokmanovic M; Hirsch DS; Shen Y; Wu WJ
    Mol Cancer Ther; 2009 Jun; 8(6):1557-69. PubMed ID: 19509242
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Trastuzumab regulates IGFBP-2 and IGFBP-3 to mediate growth inhibition: implications for the development of predictive biomarkers for trastuzumab resistance.
    Dokmanovic M; Shen Y; Bonacci TM; Hirsch DS; Wu WJ
    Mol Cancer Ther; 2011 Jun; 10(6):917-28. PubMed ID: 21487052
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Trastuzumab signaling in ErbB2-overexpressing inflammatory breast cancer correlates with X-linked inhibitor of apoptosis protein expression.
    Aird KM; Ding X; Baras A; Wei J; Morse MA; Clay T; Lyerly HK; Devi GR
    Mol Cancer Ther; 2008 Jan; 7(1):38-47. PubMed ID: 18202008
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Potent anti-proliferative effects of metformin on trastuzumab-resistant breast cancer cells via inhibition of erbB2/IGF-1 receptor interactions.
    Liu B; Fan Z; Edgerton SM; Yang X; Lind SE; Thor AD
    Cell Cycle; 2011 Sep; 10(17):2959-66. PubMed ID: 21862872
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HDAC inhibitor SNDX-275 enhances efficacy of trastuzumab in erbB2-overexpressing breast cancer cells and exhibits potential to overcome trastuzumab resistance.
    Huang X; Wang S; Lee CK; Yang X; Liu B
    Cancer Lett; 2011 Aug; 307(1):72-79. PubMed ID: 21497990
    [TBL] [Abstract][Full Text] [Related]  

  • 9. p130Cas scaffold protein regulates ErbB2 stability by altering breast cancer cell sensitivity to autophagy.
    Bisaro B; Sciortino M; Colombo S; Camacho Leal MP; Costamagna A; Castellano I; Montemurro F; Rossi V; Valabrega G; Turco E; Defilippi P; Cabodi S
    Oncotarget; 2016 Jan; 7(4):4442-53. PubMed ID: 26716506
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PC cell-derived growth factor stimulates proliferation and confers Trastuzumab resistance to Her-2-overexpressing breast cancer cells.
    Kim WE; Serrero G
    Clin Cancer Res; 2006 Jul; 12(14 Pt 1):4192-9. PubMed ID: 16857791
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mek activity is required for ErbB2 expression in breast cancer cells detached from the extracellular matrix.
    Khan IA; Yoo BH; Rak J; Rosen KV
    Oncotarget; 2017 Dec; 8(62):105383-105396. PubMed ID: 29285258
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Granulocyte-colony stimulating factor upregulates ErbB2 expression on breast cancer cell lines and converts primary resistance to trastuzumab.
    Cavalloni G; Sarotto I; Pignochino Y; Gammaitoni L; Migliardi G; Sgro L; Piacibello W; Risio M; Aglietta M; Leone F
    Anticancer Drugs; 2008 Aug; 19(7):689-96. PubMed ID: 18594210
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Correction to: Determining the effects of trastuzumab, cetuximab and afatinib by phosphoprotein, gene expression and phenotypic analysis in gastric cancer cell lines.
    Ebert K; Zwingenberger G; Barbaria E; Keller S; Heck C; Arnold R; Hollerieth V; Mattes J; Geffers R; Raimúndez E; Hasenauer J; Luber B
    BMC Cancer; 2020 Nov; 20(1):1127. PubMed ID: 33225928
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cardiac Outcomes of Patients Receiving Adjuvant Weekly Paclitaxel and Trastuzumab for Node-Negative, ERBB2-Positive Breast Cancer.
    Dang C; Guo H; Najita J; Yardley D; Marcom K; Albain K; Rugo H; Miller K; Ellis M; Shapira I; Wolff AC; Carey LA; Moy B; Groarke J; Moslehi J; Krop I; Burstein HJ; Hudis C; Winer EP; Tolaney SM
    JAMA Oncol; 2016 Jan; 2(1):29-36. PubMed ID: 26539793
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cardiac toxicity of ErbB2-targeted therapies: what do we know?
    Perez EA
    Clin Breast Cancer; 2008 Mar; 8 Suppl 3():S114-20. PubMed ID: 18777950
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An anti-ErbB2 fully human antibody circumvents trastuzumab resistance.
    Lu Q; Wang L; Zhang Y; Yu X; Wang C; Wang H; Yang Y; Chong X; Xia T; Meng Y; Wang Y; Lu C; Zhou L; Li B
    Oncotarget; 2016 Oct; 7(41):67129-67141. PubMed ID: 27564098
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The anti-ErbB2 antibody H2-18 and the pan-PI3K inhibitor GDC-0941 effectively inhibit trastuzumab-resistant ErbB2-overexpressing breast cancer.
    Wang L; Yu X; Wang C; Pan S; Liang B; Zhang Y; Chong X; Meng Y; Dong J; Zhao Y; Yang Y; Wang H; Gao J; Wei H; Zhao J; Wang H; Hu C; Xiao W; Li B
    Oncotarget; 2017 Aug; 8(32):52877-52888. PubMed ID: 28881779
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hsp90 inhibitor 17-AAG reduces ErbB2 levels and inhibits proliferation of the trastuzumab resistant breast tumor cell line JIMT-1.
    Zsebik B; Citri A; Isola J; Yarden Y; Szöllosi J; Vereb G
    Immunol Lett; 2006 Apr; 104(1-2):146-55. PubMed ID: 16384610
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mechanisms of ErbB2-mediated paclitaxel resistance and trastuzumab-mediated paclitaxel sensitization in ErbB2-overexpressing breast cancers.
    Yu D
    Semin Oncol; 2001 Oct; 28(5 Suppl 16):12-7. PubMed ID: 11706391
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hyaluronan-induced masking of ErbB2 and CD44-enhanced trastuzumab internalisation in trastuzumab resistant breast cancer.
    Pályi-Krekk Z; Barok M; Isola J; Tammi M; Szöllosi J; Nagy P
    Eur J Cancer; 2007 Nov; 43(16):2423-33. PubMed ID: 17911008
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.